Day 1Monday, 18 March 2024

Location: Room 112

2024 marks the fifth instalment of In Vivo's 'Rising Leaders' list, a groundbreaking compilation that spotlights the trailblazers shaping the future of healthcare. The Rising Leaders list is focused on a diverse cohort of entrepreneurs and innovators who represent the next wave of creativity in the industry. This distinguished list features academics, CEOs of small and mid-sized companies, and rising employees in larger biopharma and MedTech businesses, showcasing a rich tapestry of talent across the healthcare landscape. Not confined by age, these individuals have been recognized for bringing something truly innovative and transformative to the healthcare game.

At Bio-Europe Spring, former stars and company creation experts discuss trends in the industry impacting innovation and risk-taking for the next generation of biopharma leaders.

Delve into their remarkable achievements, talent, creativity, and robust leadership qualities that set them apart. This session is a unique opportunity to gain insights into the dynamic profiles of these rising stars and understand how they are shaping the future of healthcare.

The Rising Leaders series extends beyond this session, offering exclusive interviews with innovators and disruptors, coupled with insights from established industry executives on fostering the next generation of talent and building the best teams. 

Location: Room 112

This session dives into the ever-evolving landscape of dealmaking and M&A and unravels the forces reshaping the industry's dynamics. Hear real-world case studies and expert insights on strategies for forging strategic alliances, securing partnerships and driving innovation, to address the healthcare challenges of the future. Whether you're a pharmaceutical executive, investor, or innovator, this session navigates the intricacies of dealmaking and provides guidance for success, in 2024 and beyond.

Location: Exhibit Hall Stage

Did you know that healthcare systems account for more CO2 emissions than the aviation or shipping sectors? Industry leaders admit that they have a responsibility to implement sustainable strategies for the good of the world. They also see these strategies as strategic differentiators that help them build brand equity and position themselves commercially: as governments and payers increasingly view sustainability as a factor in determining reimbursement rates, there are strong incentives for biopharma businesses to embrace sustainable practices.

But what does sustainability really mean for biopharma, and where can the greatest advances in sustainable biopharma be made?

Join the panel of thought leaders across the life science ecosystem to gain insights and expert perspectives into collaborative initiatives, innovative strategies, and industry-wide commitments, in efforts to advance sustainability in the diverse life science industry. It's time to extend the principle of "first, do not harm" to the planet.

Location: Exhibit Stage Hall

This fireside chat will delve into the domestic and international life sciences sector impact of the Inflation Reduction Act. The discussion will include how the legislation is poised to shape and redefine the landscape, both in the US and abroad, changing research priorities and re-shaping biotech investment internationally.

Location: Room 111

A partner with strong commitment:

Servier is an independent pharmaceutical company committed to therapeutic progress to serve patient needs. Its unique governance allows Servier to reinvest all its profits to support its development, as well as plan and invest with a long-term view, in line with its vocation. Servier's long-term vision applies to its partnership philosophy.

A partner with a global presence:

With €4.9Bn of revenue in 2022 across 150 countries worldwide, the Group has a growing presence in the USA and Japan, a strong EU presence and a deep knowledge of emerging countries and China.

A partner with proven expertise and experience:

Servier is very focused on specialty care oncology with a proven expertise of over 60 years in cardiovascular and metabolic diseases. It is developing new therapeutic solutions to serve unmet patient needs. From R&D to commercialization, we have proven experience to help new therapeutic innovations become reality for patients, alone or with partners.

A partner you can rely on:

Servier is proud of what has been achieved with its partners so far. Servier has a strong track record of providing flexible partnership structures to its many partners, as well as an R&D infrastructure with 2,900 people in France, Hungary and Boston and an extensive commercial knowledge of global markets.

Location: Room 111

This session unravels the global exclusive license agreement between the Menarini Group and Insilico Medicine for the novel KAT6 inhibitor, a potential treatment for breast cancer and other oncology indications. Hear about the factors which drove Menarini’s interest, how the deal got started, the influence of artificial intelligence, the challenges faced in securing the deal and much more. 

Location: Room 111

Almirall is a leading global biopharmaceutical company focused on Medical Dermatology. Founded in 1944 and with headquarters in Barcelona (Spain), our Noble Purpose is at the core of our work: "Transform the patients' world by helping them realize their hopes and dreams for a healthy life".

Through pharmaceutical innovation, investment in R&D and strong commitment to global healthcare partnerships, we develop and commercialize solutions with specific focus on dermatological diseases such as psoriasis, actinic keratosis, atopic dermatitis or acne. We care and listen to our patients' needs. We find solutions for them.

Almirall’s 1800 employees are devoted to science in Medical Dermatology. In 2023, we totaled €895 MM of sales through a direct presence in 21 countries with 15 affiliates (US and EU included) and a robust network of regional partners distributing our drugs in 70 additional countries.

Almirall is listed on the Spanish Stock Exchange (ticker:ALM).

We seek building value-creating partnership across the R&D continuum (from early research to late clinical) to make a significant difference in patients’ lives.

For more information, please visit our web at www.almirall.com

Location: Room 111

This session will provide a holistic perspective with insights from industry, regulators, hospitals, and investors on navigating the challenges and opportunities in the Advanced Therapies field, ensuring a well-prepared ecosystem for the upcoming wave of innovative therapies.

Location: Room 133/134

Pick up your lunch and join us for this interactive workshop for delegates familiar with partnering who want to up their game. We will cover best practices for collaborating with colleagues, saving time, increasing response rates and acceptance rates, and partneringONE power features to support optimal partnering etiquette. Come away from the session with a clear understanding of how partneringONE can support your company to maximize ROI from partnering, at this and future events. There will be plenty of opportunities to ask our partneringONE expert any questions you may have.

This session is limited to 40 people. Please reserve your seat by adding the session to your personal agenda. If you can’t attend a session, drop by the partnering help desk with any questions.